Michael Liptay to Middle Aged
This is a "connection" page, showing publications Michael Liptay has written about Middle Aged.
Connection Strength
0.346
-
Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol. 2009 Dec 15; 100(8):703-7.
Score: 0.043
-
Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
Score: 0.042
-
Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg. 2010 Mar; 139(3):606-11.
Score: 0.042
-
Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
Score: 0.040
-
Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol. 2018 Jul; 79(7):558-563.
Score: 0.019
-
Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
Score: 0.015
-
Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
Score: 0.015
-
Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
Score: 0.015
-
Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
Score: 0.014
-
Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
Score: 0.013
-
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
Score: 0.013
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.013
-
Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
Score: 0.012
-
A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
Score: 0.011
-
Cytologic features of adult spindle cell variant of rhabdomyosarcoma: a report of two cases. Diagn Cytopathol. 2009 Dec; 37(12):932-4.
Score: 0.011
-
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug; 45(2):243-53.
Score: 0.007
-
Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997 Apr; 113(4):691-8; discussion 698-700.
Score: 0.004
-
Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997 Feb; 63(2):334-8.
Score: 0.004
-
Small pulmonary lesions detected at CT: clinical importance. Radiology. 1997 Jan; 202(1):105-10.
Score: 0.004
-
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996 Sep; 224(3):288-94; discussion 294-6.
Score: 0.004
-
Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg. 1996 Mar; 61(3):977-82.
Score: 0.004